-
Uncategorized2 months ago
Trump, FDA plan to expedite psychedelic development
Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedite their research and development as remedies for severe mental health...
-
Uncategorized2 months agoRFK Jr. defends HHS tenure, 12% proposed budget cut
Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised concerns about proposed budget cuts to the...
-
Uncategorized2 months ago
Novartis cuts two programs in cancer-related blood clots
Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial. The move marks a setback for a candidate...
-
Uncategorized2 months ago
Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline
Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, the companies said today, in a deal that would bolster the buyer’s oncology...
-
Uncategorized2 months agoSTAT+: Trump order to advance psychedelic treatments generates excitement — and worries
President Trump’s executive order aimed at loosening restrictions on psychedelics as mental health treatments was largely applauded by advocates. But some also quietly worry the White...
-
Uncategorized2 months ago
AACR 2026: Cancers of Unknown Primary Identified by DNA Methylation AI Model
SAN DIEGO – Researchers from Kindai University in Japan have developed a machine learning model that accurately predicts the origin of diverse cancer types in patients...
-
Uncategorized2 months ago
Viatris recalls extended-release Xanax over dissolution test failure
Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an analysis revealed an issue that could affect bioavailability.
-
Uncategorized2 months agoNektar surges again as alopecia drug shows new promise in extension study
Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, extending a comeback bid that’s caused shares to...
-
Uncategorized2 months ago
Merck partner reveals bispecific data; Biogen pays $100M for antibody rights
Merck partner reveals bispecific data; Biogen pays $100M for antibody rights
-
Uncategorized2 months agoSTAT+: The PBMs fight back, and arbitration doesn’t lose
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Did you know it’s National Library Week? Of course you did,...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
